###### Strengths and limitations of this study

This is the first systematic review and meta-analysis to compare the perioperative outcomes of percutaneous nephrolithotomy in patients with or without previous ipsilateral open renal surgery.Methodological quality of each study was assessed using the Newcastle-Ottawa Scale for non-randomised controlled trials, and heterogeneity test, bias assessment, meta-analysis and sensitivity analysis were also conducted.Substantial heterogeneity was observed for several outcomes.The risk of selecting and reporting bias cannot be totally excluded due to the retrospective approach of data collection in the included studies.

Introduction {#s1}
============

The lifetime risk of kidney stone formation is approximately 11% for men and 7% for women, which has a tendency to increase with changes in diet and climate.[@R1] It is anticipated that other pre-existing medical conditions, such as diabetes and obesity, will further increase an individual\'s risk of developing nephrolithiasis.[@R2] Besides a high prevalence, renal stone disease also has a tendency to recur if left untreated, with a reported recurrence rate as high as 50% at 5 years and 80--90% at 10 years, respectively.[@R3]

Percutaneous nephrolithotomy (PCNL), first reported by Fernstrom and Johansson in 1976, has almost replaced open surgery as the main treatment for large or multiple kidney stones, and has been used in cases of failed shock wave lithotripsy, in most countries.[@R4] [@R5] However, open renal surgery and its influence have not become obsolete. Some patients treated today have undergone open nephrolithotomy in the past due to the high recurrence rate of urolithiasis. Furthermore, open surgery still plays an essential role in special medical circumstances where minimally invasive interventions may not be suitable, and in many peripheral regions of developing countries, where PCNL is not freely available.[@R6] [@R7] With the recurrence rate for renal stones, these patients may also need PCNL intervention in the future. Patients with previous open renal surgery (POS) will often have retroperitoneal scar tissue around the kidney, distortion of the pelvicaliceal anatomy and, in some cases, bowel displacement. In general, when performing surgery in an anatomical region that has previously been operated on, the surgeon can expect a technical challenge that may be associated with a longer operating time, higher complication rate and, possibly, a lower success rate.

Does POS affect the efficiency and safety of subsequent PCNL? Various studies have sought to compare the outcomes of PCNL in patients with or without a history of open renal surgery.[@R8] Their results have not been entirely consistent or have even been contradictory, with some reporting lower success rates and/or higher complication risks associated with POS,[@R10] [@R13] [@R16] [@R20] [@R21] [@R23] while others have found no significant differences between the POS and non-previous open renal surgery (nPOS) groups.[@R8] [@R9] [@R11] [@R12] [@R17] [@R22] [@R24] Despite numerous studies being carried out since the 1980s, this problem has remained a contentious issue that is still debated today. The aim of this study was to perform a systematic review of all available evidence comparing surgical outcomes of PCNL in patients with or without POS, and to provide an answer using a meta-analysis approach.

Materials and methods {#s2}
=====================

A study protocol was developed and is provided as an [online supplementary material](#SM1){ref-type="supplementary-material"} file.
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Literature searches and study selection {#s2a}
---------------------------------------

A systematic literature database search in PubMed, Web of Science and the Cochrane Library was performed to identify relevant studies, on 10 September 2015. The search was limited by neither year nor language, and followed Cochrane standards and guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analyses.[@R25] The strategy was designed to retrieve all published original articles containing the following search terms: ('lumbotomy' OR 'open') AND ('percutaneous nephrolithotomy' OR 'percutaneous nephrolithotripsy' OR 'PCNL' OR 'PNL'). Two authors, namely HH and YL, independently screened all of the citations returned from the search strategy, to identify potentially eligible studies. Studies comparing the perioperative outcomes of PCNL in patients with or without POS were screened further. Conference abstracts were not included, as they were deemed methodologically inappropriate. Disagreements were resolved through discussions until a consensus was reached.

Data extraction and study quality assessment {#s2b}
--------------------------------------------

The authors identifying the included studies also independently extracted and summarised the following data: participant characteristics, study design and duration, sample size, inclusion/exclusion criteria, matching criteria and reported perioperative outcomes. The methodological quality of each study was assessed by the two authors mentioned above using the Newcastle-Ottawa Scale for non-randomised controlled trials.[@R26] Possible publication bias was assessed using funnel plots of the outcome comparisons.

Statistical analysis {#s2c}
--------------------

A meta-analysis was performed using Review Manager Software V.5.3 (RevMan V.5.3, The Cochrane Collaboration, Oxford, UK). The weighted-mean difference (WMD) and relative risk (RR) with 95% CIs were used as the summary statistics for continuous and dichotomous variables, respectively. For studies presenting continuous data as means and ranges, the SDs were estimated using the methodology described by Hozo *et al*.[@R27] Heterogeneity between studies was assessed using the χ^2^ test and I^2^ statistics. Pooled estimates were calculated using a fixed-effects model, unless significant heterogeneity was detected, in which case a random-effects model was applied. The pooled effects were determined using a z-test. A two-sided p value \<0.05 was used to indicate statistical significance. Funnel plots were generated in order to screen for potential publication bias. Additional sensitivity analyses were performed by ruling out studies in which participants of the two groups were not equally matched.

Results {#s3}
=======

Literature searches and characteristics of the included studies {#s3a}
---------------------------------------------------------------

[Figure 1](#BMJOPEN2015010627F1){ref-type="fig"}A illustrates the flow diagram of both included and excluded studies identified. After referring to the full texts, 17 studies involving 4833 procedures (4784 patients) of which 1431 were in the POS group and 3402 in the nPOS group, were enrolled for analysis. Full-text screening was performed for three studies and these were finally excluded because of lack of a control group or because the data in the studies were confused.[@R28] The characteristics of those identified studies are summarised in [table 1](#BMJOPEN2015010627TB1){ref-type="table"}. Eight of the studies were conducted in Turkey, two in Iran, two in India and one each in Brazil, China, Egypt, Israel and Thailand. All of the studies were retrospective cohort studies, and it is impossible to have designed them as randomised controlled studies, for patients could not be randomly divided into groups with or without POS. The inclusion criteria of the POS group were previous ipsilateral open stone surgery in 16 studies[@R8] [@R18] and open renal operations in one.[@R17] The reasons that patients required open renal surgeries in the last study were not explicitly described, although they were probably due to stone diseases.[@R17] Conversely, the inclusion criteria of the nPOS group were primary PCNL without POS. All procedures were carried out under general anaesthesia with the guidance of fluoroscopy, with the exception of one clinical team from China, which used epidural anaesthesia under the guidance of ultrasound.[@R19] All of the patients were placed in the prone position with the majority receiving standard PCNL; however, in some studies, selected patients received minimally invasive[@R17] [@R19] [@R21] [@R24] (tract size ≤22F) or tubeless PCNL instead.[@R11] [@R15] [@R16] Most trials used pneumolithotripsy,[@R13] [@R18] [@R24] while others used ultrasonic lithotripter[@R8] [@R9] or were mixed.[@R10] [@R12] [@R16] [@R17] The studies were rated according to the Newcastle-Ottawa Scale as being relatively high in quality. The baseline characteristics were directly comparable between the two groups in most studies.[@R8] [@R10] [@R14] [@R24] Significant differences were observed, however, in respect to the sex ratio, age or renal stone burden, in four studies, which are also shown in [table 1](#BMJOPEN2015010627TB1){ref-type="table"}.[@R9] [@R13] [@R21] [@R23] Additionally, a sensitivity analysis was performed in order to detect and rule out any potential bias associated with the effects of such studies on the results as a whole. We analysed possible publication bias by generating funnel plots of all the evaluated comparisons of outcomes. As an example, [figure 1](#BMJOPEN2015010627F1){ref-type="fig"}B represents the funnel plot of the comparison for initial stone-free rate (SFR), which included the most patients. It shows no obvious asymmetry, suggesting that publication bias was not significant.

###### 

Characteristics of included studies

  Studies                     Year   Country    Duration     Study design   Study quality   Groups   Renal units   Patient number   Mean/median age (SD/range) (year)   Sex M/F   Side L/R   Stone diameter/area (SD/range) (mm/mm^2^)
  --------------------------- ------ ---------- ------------ -------------- --------------- -------- ------------- ---------------- ----------------------------------- --------- ---------- -------------------------------------------
  Netto *et al*[@R8]          1988   Brazil     NA           RCS            8/9             POS      84            79               45 (9--72)                          47/32     NA         NA
                                                                                            nPOS     150           145              49 (18--75)                         83/62     NA         NA
  Basiri *et al*[@R9]         2003   Iran       1990--1999   RCS            6/9             POS      65            65               40 (14--74)                         51/14\*   32/33      30
                                                                                            nPOS     117           117              43 (13--75)                         73/44\*   70/47      35
  Margel *et al*[@R10]        2005   Israel     2000--2003   RCS            8/9             POS      21            21               52\* (41--72)                       15/6      NA         27 (19)
                                                                                            nPOS     146           146              45\* (10--78)                       96/50     NA         29.5 (17)
  Lojanapiwat *et al*[@R11]   2006   Thailand   NA           RCS            8/9             POS      178           175              50.64 (12.38)                       111/64    86/92      38.6 (16.8)
                                                                                            nPOS     178           175              50.61 (12.62)                       114/61    96/82      38.1 (15.5)
  Sofikerim *et al*[@R12]     2007   Turkey     2005--2006   RCS            8/9             POS      27            27               45.4 (18--74)                       16/11     17/10      361.3 (100--900)
                                                                                            nPOS     62            62               44 (18--75)                         33/29     37/25      482.4 (84--1000)
  Kurtulus *et al*[@R13]      2008   Turkey     2003--2007   RCS            7/9             POS      142           142              45.7 (21--67)                       85/47     NA         1150 (150--11500)\*
                                                                                            nPOS     186           186              43.5 (18--80)                       120/66    NA         735 (100--5600)\*
  Tugcu *et al*[@R14]         2008   Turkey     2004--2006   RCS            8/9             POS      55            55               42 (22--70)                         22/35     27/28      385.6 (110--730)
                                                                                            nPOS     105           105              45 (16--72)                         49/58     54/51      401.1 (100--8100)
  Falahatkar *et al*[@R15]    2009   Iran       2005--2007   RCS            8/9             POS      36            36               47.4 (13.69)                        22/14     16/20      35.33 (32.76)
                                                                                            nPOS     68            68               44 (13.50)                          31/37     31/37      35.13 (21.56)
  Gupta *et al*[@R16]         2009   India      2005--2007   RCS            8/9             POS      66            66               35.2 (10--70)                       40/26     24/42      33 (20--60)
                                                                                            nPOS     90            90               33.5 (6--72)                        55/35     38/52      35 (22--60)
  Resorlu *et al*[@R17]       2010   Turkey     2006--2009   RCS            9/9             POS      132           132              44.1 (14--66)                       71/59     67/65      820 (520)
                                                                                            nPOS     192           192              41.2 (0.75--70)                     112/87    95/92/5    780 (430)
  Gupta *et al*[@R18]         2011   India      2009--2010   RCS            9/9             POS      45            45               40.6 (12.30)                        27/18     25/20      30 (23)
                                                                                            nPOS     55            55               35.51 (11.10)                       36/19     30/25      28 (15)
  Zhang *et al*[@R19]         2011   China      2006--2011   RCS            8/9             POS      34            34               54.1 (13.80)                        12/22     20/14      NA
                                                                                            nPOS     64            64               54.6 (11.80)                        24/40     35/29      NA
  Yesil *et al*[@R20]         2013   Turkey     2007--2010   RCS            8/9             POS      42            42               40.61 (12.30)                       NA        NA         189.57 (94.23)
                                                                                            nPOS     232           232              44.34 (12.75)                       NA        NA         177.33 (86.18)
  Onal *et al*[@R21]          2014   Turkey     2000--2011   RCS            7/9             POS      26            23               8.51 (5.17)\*                       13/10     12/14      513 (337)
                                                                                            nPOS     97            88               6.29 (4.37)\*                       56/32     43/54      409 (328)
  Aldaqadossi *et al*[@R22]   2015   Egypt      2008--2014   RCS            8/9             POS      48            40               7.9 (4.2)                           27/13     22/26      32 (2.9)
                                                                                            nPOS     87            81               7.3 (3.50)                          49/32     48/39      32 (3.6)
  Ozgor *et al*[@R23]         2015   Turkey     2002--2015   RCS            8/9             POS      410           410              45.4 (13.5)                         258/152   208/202    830 (630)
                                                                                            nPOS     1529          1529             44.3 (13.9)                         875/654   821/708    780 (570)
  Telli *et al*[@R24]         2015   Turkey     2000--2014   RCS            8/9             POS      20            18               10.4 (4.20)                         12/6      11/9       36.5 (24.2)
                                                                                            nPOS     44            39               8.8 (4.50)                          27/12     25/19      33.1 (21.6)

\*Significantly different between two groups.

(n)POS, (non-) previous open renal surgery group; L/R, left/right; M/F, male/female; NA, not available; RCS, retrospective cohort studies.

![(A) Flowchart of the studies selection process. (B) Funnel plot of initial stone-free rate.](bmjopen2015010627f01){#BMJOPEN2015010627F1}

Meta-analysis of perioperative outcomes {#s3b}
---------------------------------------

A meta-analysis of perioperative outcomes is summarised in [table 2](#BMJOPEN2015010627TB2){ref-type="table"}. The forest and funnel plots for each comparison are represented in [online supplementary figure](#SM3){ref-type="supplementary-material"} 1--42. As shown in [table 2](#BMJOPEN2015010627TB2){ref-type="table"}, the heterogeneity in most comparisons was moderate or low. No statistically significant differences were observed between POS and nPOS groups in terms of supracostal access (RR, 0.89; 95% CI 0.72 to 1.11; p=0.31), single tracts (RR, 1.00; 95% CI 0.97 to 1.03; p=0.89), multiple tracts (RR, 1.11; 95% CI 0.83 to 1.47; p=0.49), metal dilator need (RR, 5.02; 95% CI 0.96 to 26.19; p=0.06), time required to access the collecting system (WMD, 0.85 min; 95% CI −0.82 to 2.53; p=0.32), fluoroscopic duration (WMD, 0.01 min; 95% CI −0.24 to 0.25; p=0.95), demand for analgaesics (WMD, 6.06 mg; 95% CI 0.12 to 11.99; p=0.05), hospital stay (WMD, 0.06 d; 95% CI −0.10 to 0.22; p=0.47), final stone-free rate (RR, 1.00; 95% CI 0.98 to 1.03; p=0.78), the risk of total complications (RR, 1.03; 95% CI 0.89 to 1.19; p=0.69) and risk of developing certain complications such as fever (RR, 1.05; 95% CI 0.70 to 1.58; p=0.80), haemorrhage (RR, 1.02; 95% CI 0.71 to 1.46; p=0.93), haemo/hydro/pneumothorax (RR, 0.93; 95% CI 0.51 to 1.69; p=0.80), blood transfusion (RR, 1.10; 95% CI 0.86 to 1.39; p=0.45), urinary tract infection (RR, 1.42; 95% CI 0.93 to 2.15; p=0.10) and sepsis (RR, 1.07; 95% CI 0.31 to 3.66; p=0.92). Patients with POS, however, had a greater drop in haemoglobin (WMD, 1.78 g/L; 95% CI 1.09 to 2.47; p\<0.00001) accompanied by a higher risk of bleeding requiring angiographic embolisation (RR, 3.73; 95% CI 1.36 to 10.21; p=0.01), lower initial SFR (RR, 0.96; 95% CI 0.92 to 0.99; p=0.007) and more secondary treatment (RR, 1.61; 95% CI 1.09 to 2.37; p=0.02).
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###### 

Meta-analyses of perioperative clinical outcomes

                                                                                                                Sample size   Tests for heterogeneity           Test for overall effect   Event rate (%)   RR/WWD                                         
  ------------------------------- ----------------------------------------------------------------------------- ------------- ------------------------- ------- ------------------------- ---------------- ----------- ----------- ---------------------- ------
  Operative time (min)            [@R9]^,^ [@R14]                                                               1205/3066     54%                       0.006   Random                    2.04             0.04        --          3.55 (0.14 to 6.97)    nPOS
  Supracostal access              [@R11]^,^ [@R12]^,^ [@R16]^,^ [@R21]                                          755/2043      0%                        0.97    Fixed                     1.02             0.31        12.8/13.5   0.89 (0.72 to 1.11)    POS
  Single tract                    [@R9]^,^ [@R13]^,^ [@R15]^,^ [@R17]^,^ [@R19]^,^ [@R21]^,^ [@R22]^,^ [@R24]   702/1179      0%                        0.80    Fixed                     0.14             0.89        90.5/91.5   1.00 (0.97 to 1.03)    None
  Requiring multiple tracts       [@R9]^,^ [@R13]^,^ [@R15]^,^ [@R17]^,^ [@R19]^,^ [@R21]^,^ [@R22]^,^ [@R24]   702/1179      0%                        0.97    Fixed                     0.68             0.49        9.5/8.5     1.11 (0.83 to 1.47)    nPOS
  Needing metal dilator           [@R8]^,^ [@R11]^,^ [@R13]^,^ [@R16]                                           470/604       80%                       0.002   Random                    1.91             0.06        8.4/16.8    5.02 (0.96 to 26.19)   nPOS
  Tract establishing time (min)   [@R17]^,^ [@R24]                                                              152/236       0%                        0.86    Fixed                     1.00             0.32        --          0.85 (−0.82 to 2.53)   nPOS
  Fluoroscopic time (min)         [@R17]^,^ [@R20]                                                              678/2181      33%                       0.19    Fixed                     0.06             0.95        --          0.01 (−0.24 to 0.25)   nPOS
  Analgesics demand (mg)          [@R11]^,^ [@R12]^,^ [@R16]^,^ [@R22]                                          319/417       44%                       0.72    Fixed                     2.00             0.05        --          6.06 (0.12 to 11.99)   nPOS
  Haemoglobin drop (g/L)          [@R10]^,^ [@R18]^,^ [@R20]^,^ [@R22]                                          697/2139      31%                       0.20    Fixed                     5.07             \<0.00001   --          1.78 (1.09 to 2.47)    nPOS
  Fever                           [@R15]^,^ [@R22]                                                              689/1934      0%                        0.84    Fixed                     0.26             0.80        4.0/5.8     1.05 (0.70 to 1.58)    nPOS
  Haemorrhage                     [@R8]^,^ [@R9]^,^ [@R18]^,^ [@R20]^,^ [@R22]^,^ [@R24]                        304/685       64%                       0.02    Random                    0.09             0.93        6.1/9.9     1.02 (0.71 to 1.46)    nPOS
  Haemo/hydro/pneumothorax        [@R8]^,^ [@R11]^,^ [@R12]^,^ [@R16]^,^ [@R21]                                 1016/2440     0%                        0.91    Fixed                     0.25             0.80        1.3/1.4     0.93 (0.51 to 1.69)    POS
  Blood transfusion               [@R8]^,^ [@R11]^,^ [@R17]^,^ [@R18]^,^ [@R20]                                 1245/2985     0%                        0.69    Fixed                     0.76             0.45        6.4/7.6     1.10 (0.86 to 1.39)    nPOS
  Urinary tract infection         [@R9]^,^ [@R12]^,^ [@R13]^,^ [@R17]^,^ [@R18]^,^ [@R21]^,^ [@R22]             457/753       0%                        0.91    Fixed                     1.64             0.10        6.2/8.1     1.42 (0.93 to 2.15)    nPOS
  Sepsis                          [@R11]^,^ [@R14]^,^ [@R17]                                                    365/475       8%                        0.34    Fixed                     0.11             0.92        1.1/1.1     1.07 (0.31 to 3.66)    nPOS
  Angiographic embolisation       [@R9] [@R13] [@R19] [@R20] [@R23]                                             693/2128      37%                       0.17    Fixed                     2.55             0.01        0.3/1.0     3.04 (1.29 to 7.16)    nPOS
  Total complications             [@R9]^,^ [@R21]                                                               1271/2956     0%                        0.99    Fixed                     0.40             0.69        14.8/16.8   1.03 (0.89 to 1.19)    nPOS
  Hospital stay(d)                [@R11]^,^ [@R12]^,^ [@R14]                                                    1119/2803     63%                       0.001   Random                    0.72             0.47        --          0.06 (−0.10 to 0.22)   nPOS
  Secondary procedure             [@R10]^,^ [@R16]^,^ [@R19]                                                    523/831       64%                       0.01    Random                    2.41             0.02        18.7/27.3   1.61 (1.09 to 2.37)    nPOS
  Initial SRF                     [@R8]^,^ [@R9]^,^ [@R11]^,^ [@R21]                                            1334/2960     15%                       0.29    Fixed                     2.68             0.007       82.2/78.9   0.96 (0.92 to 0.99)    nPOS
  Final SRF                       [@R8] [@R13] [@R15] [@R19]                                                    580/1013      0%                        0.79    Fixed                     0.28             0.78        92.7/93.4   1.00 (0.98 to 1.03)    None

\*p Values less than 0.05 were considered statistically significant. (n)POS, (non-) previous open renal surgery group; RR, relative risk; SFR, stone-free rate; WMD weighted mean difference.

Sensitivity analysis {#s3c}
--------------------

Further sensitivity analysis was performed by removing studies in which patients\' baseline characteristics were not well matched. As shown in [table 3](#BMJOPEN2015010627TB3){ref-type="table"}, except for differences in operative time and initial SFR, which turned out to be insignificant (p=0.16 and 0.69, respectively), sensitivity analyses generated comparable results that affected the degree rather than the direction or significance of the effect.

###### 

Sensitivity analysis results

                                                                                                                                Sample size   Tests for heterogeneity           Test for overall effect   RR/WWD                                        
  --------------------------- ------------------------------------------------------------------------------------------------- ------------- ------------------------- ------- ------------------------- -------- ----------- ------------------------ ------
  Operative time (min)        [@R10]^,^ [@R14]^,^ [@R23]^,^ [@R24]                                                              704/1323      60%                       0.004   Random                    1.54     0.12        3.51 (−0.96 to 7.99)     nPOS
  Supracostal access          [@R11]^,^ [@R12]^,^ [@R16]^,^ [@R22]                                                              319/417       0%                        0.86    Fixed                     0.86     0.39        0.87 (0.64 to 1.19)      POS
  Single tract                [@R10]^,^ [@R11]^,^ [@R15]^,^ [@R17]^,^ [@R19]^,^ [@R22]^,^ [@R24]                                469/799       0%                        0.98    Fixed                     0.62     0.54        0.99 (0.95 to 1.03)      nPOS
  Requiring multiple tracts   [@R10]^,^ [@R11]^,^ [@R15]^,^ [@R17]^,^ [@R19]^,^ [@R22]^,^ [@R24]                                469/799       0%                        1.00    Fixed                     0.62     0.53        1.12 (0.79 to 1.58)      nPOS
  Needing metal dilator       [@R8]^,^ [@R11]^,^ [@R16]                                                                         328/418       84%                       0.002   Random                    1.43     0.15        6.10 (0.51 to 73.33)     nPOS
  Fluoroscopic time (min)     [@R17]^,^ [@R20]^,^ [@R22]^,^ [@R24]                                                              652/2084      0%                        0.66    Fixed                     1.00     0.32        −0.14 (−0.41 to 0.13)    nPOS
  Haemoglobin drop (g/L)      [@R17]^,^ [@R18]^,^ [@R20]^,^ [@R22]^,^ [@R24]                                                    287/610       30%                       0.22    Fixed                     5.03     \<0.00001   2.03 (1.24 to 2.82)      nPOS
  Haemorrhage                 [@R8]^,^ [@R18]^,^ [@R20]^,^ [@R22]^,^ [@R24]                                                     239/568       71%                       0.008   Random                    0.96     0.34        1.59 (0.62 to 4.06)      nPOS
  Haemo/hydro/pneumothorax    [@R8]^,^ [@R11]^,^ [@R12]^,^ [@R16]^,^ [@R22]                                                     580/814       0%                        0.79    Fixed                     0.03     0.98        0.99 (0.49 to 2.01)      POS
  Blood transfusion           [@R8]^,^ [@R11]^,^ [@R12]^,^ [@R14]^,^ [@R15]^,^ [@R17]^,^ [@R18]^,^ [@R20]^,^ [@R22]^,^ [@R24]   619/1173      0%                        0.50    Fixed                     1.00     0.32        1.20 (0.84 to 1.70)      nPOS
  Urinary tract infection     [@R12]^,^ [@R17]^,^ [@R18]^,^ [@R22]                                                              224/353       0%                        0.84    Fixed                     1.72     0.09        1.60 (0.94 to 2.74)      nPOS
  Angiographic embolisation   [@R19]^,^ [@R20]                                                                                  76/296        0%                        0.32    Fixed                     3.08     0.002       18.88 (2.91 to 122.26)   nPOS
  Total complication          [@R10]^,^ [@R14]^,^ [@R22]^,^ [@R24]                                                              628/1027      0%                        0.90    Fixed                     0.37     0.71        1.04 (0.86,1.25)         nPOS
  Hospital stay (d)           [@R11]^,^ [@R12]^,^ [@R14]^,^ [@R22]^,^ [@R24]                                                    683/1177      56%                       0.01    Random                    1.02     0.31        0.09 (−0.08 to 0.25)     nPOS
  Secondary procedure         [@R10]^,^ [@R14]^,^ [@R16]^,^ [@R19]                                                              381/645       55%                       0.05    Random                    2.57     0.01        1.81 (1.15 to 2.85)      nPOS
  Initial SRF                 [@R8]^,^ [@R11]^,^ [@R12]^,^ [@R14]^,^ [@R22]^,^ [@R24]                                           691/1031      0%                        0.66    Fixed                     0.40     0.69        0.99 (0.95 to 1.03)      nPOS
  Final SRF                   [@R8]^,^ [@R10]^,^ [@R15]^,^ [@R19]                                                               373/710       0%                        0.65    Fixed                     0.57     0.57        1.01 (0.98 to 1.04)      POS

\*p Values less than 0.05 were considered statistically significant.

(n)POS, (non-) previous open renal surgery group; RR, relative risk; SFR, stone-free rate; WMD, weighted mean difference.

Discussion {#s4}
==========

This meta-analysis has demonstrated no statistically significant difference in supracostal access, single/multiple tracts, metal dilator need, time required to access the collecting system, fluoroscopic duration, demand for analgesics, final SFR, hospital stay, risks of certain complications (eg, fever, haemorrhage, haemo-/hydro-/pneumothorax, blood transfusion, urinary tract infection and sepsis), or risk of total complications, between patients with or without POS. However, patients with POS had a greater drop in haemoglobin, higher risk of angiographic embolisation, more secondary procedures (eg, relook-PCNL and shock wave lithotripsy), potentially longer operative time and lower initial SFR.

Open renal surgery leads to retroperitoneal scars around the kidney that may adversely affect introduction of the access needle and prevent proper dilatation of the tract in subsequent PCNL procedures. Part of this technical difficulty is reflected in the operative time, which was 3.55 min longer in the POS group. As expected, many researchers experienced technical difficulty in the establishment of a dilated tract in the POS group;[@R10] [@R11] [@R13] [@R15] [@R18] although some studies also claim to have encountered no difficulties whatsoever.[@R12] [@R17] [@R21] [@R22] This uncertainty and the small difference in operative time generated a p value of 0.12 in the sensitivity analysis. Urologists who reported no technical difficulties had adopted serial Amplatz dilators.[@R12] [@R17] [@R22] They found the dilators to work well, even in the presence of dense scarred tissue around the kidney, because the small tip of the instrument could easily pass through the previously smaller dilated tract.[@R17] Owing to advancements in instrument development and increasing surgical experience, this difficulty can now be resolved on most occasions, which may explain why there was no difference in the time taken to establish the tract and fluoroscopy that is also partially reflective of the technical challenge.

The process of scarring after open stone surgery may also occur within the collecting system, affecting the rate of kidney stone clearance. The results of this meta-analysis demonstrate that patients with POS have a lower initial SFR and may need more auxiliary procedures; however, no significant difference was observed in initial SFR by sensitivity analysis. On the one hand, the difference in initial SFR between the two groups is very small (RR, 0.96) requiring a large sample size for detection, and on the other, this could also partially arise from differences in the definitions of SFR and pooled studies. Some studies considered residue fragments less than 4 mm to be stone-free[@R13] [@R15] [@R19] or a success,[@R11] [@R12] [@R24] while another used fragments less than 3 mm,[@R8] and in the remaining instances, the authors failed to provide a clear definition. From this meta-analysis we can only draw the conclusion that patients with POS have a higher risk of receiving secondary treatment (RR, 1.61; 95% CI 1.09 to 2.37; p=0.02) and can finally reach a SFR as primary patients.

Haemorrhage is one of the most concerning complications following PCNL. If the bleeding is severe, angiography is often required. Five studies, including 2821 patients, reported 13 cases in which angiography was performed.[@R9] [@R13] [@R19] [@R20] Eight of these patients were found to have arteriovenous fistula. A meta-analysis of these studies showed that patients with POS were associated with a higher risk of angiographic embolisation. Yesil *et al*[@R20] also reported a higher risk of vascular complications in patients with POS. PCNL after a previous operation is usually performed at a site where having anatomical alterations, inflammation and adhesions could lead to vascular problems.[@R17] Furthermore, retroperitoneal and caliceal scarring may surround the kidney, thus reducing its mobility. In these cases, intraoperative manipulation of the nephroscope may produce enough torque to cause lacerations to the kidney, with bleeding.[@R11] [@R14] This could explain the greater drop in haemoglobin in the POS group. We have also pointed out, however, that major vascular complications requiring angiography embolisation are not common in patients with POS and that a significantly greater drop in haemoglobin does not translate into greater blood transfusion.

Based on the outcomes and experiences of the urologists in this meta-analysis,[@R8] [@R24] we have outlined some key points below, which need to be considered carefully when performing PCNL in patients with POS: Preoperative evaluation. Preoperative non-contrast helical CT (NCCT) scans and intravenous urography are recommended and of importance when planning the initial access. Except for the kidney stone\'s characteristics and its relationship with the renal parenchyma, NCCT scans can detect the anatomical distortion and ascertain any possible bowel displacement, while intravenous urography can show the exact anatomy of the renal collecting system.Planning the initial access route. Owing to the difficulty in gaining access to a scarred kidney, and the typical stiffness of the scarred collecting system, it is crucial to select the single access route that will allow maximum kidney stone removal. The tract site should be decided mainly based on stone and anatomical characteristics rather than scar tissue, but making it as far from the surgical scar as possible could facilitate puncture and easy dilation. In addition, lower pole access is associated with a lower complication rate and shorter hospital stay.[@R29]Tract establishment. There may be some difficulties in dilation due to adhesions and fibrosis. This obstacle can be addressed by using serial fascial dilators in most cases where balloon dilation has resulted in undilated segments. Alternative methods may also include metal dilators and a sharp incision of the fascia.Surgical manipulation. Avoid 'rough' manipulation of the nephroscope as much as possible; this is especially important in reducing some of the major complications in POS patients. As mentioned above, retroperitoneal scarring reduces the mobility of the kidney, and rough intraoperative manipulation of instruments could produce enough torque to cause lacerations and bleeding, and may even result in major vascular complications. Kidney stone removal from a scarred collecting system is difficult, as some stones may be partially embedded in the tissue, necessitating careful checking and the use of stone graspers. This is important to improve one-session SFR.Postoperative evaluation and follow-up: pay particular attention to the early recognition of major vascular complications.

This study also has some limitations. As described above, this meta-analysis did not and could not include randomised controlled studies, so there could still be residual confounding when comparing these non-randomised groups. Two studies did not provide the data on stone size, and only three studies graded postoperative complications according to the Clavien-Dindo Classification System. The perioperative complications in these included studies might have inconsistent definitions and reporting, and the management of such complications was rarely reported; therefore, it was not possible for us to further grade and analyse. In addition, although the funnel plots do not show considerable asymmetry in these comparisons, the risk of selecting and reporting bias cannot be totally excluded due to the retrospective approach of data collection in these studies. Last but not least, statistical significance and clinical significance are not synonyms. Clinical significance should also be considered when interpreting the results of this study.

Conclusions {#s5}
===========

This meta-analysis has demonstrated that, despite having a greater drop in haemoglobin, accompanied by a higher risk of requiring angiographic embolisation and auxiliary procedures, potentially longer operative time and lower initial SFR, subsequent PCNL is not affected by POS on the ipsilateral side.
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